Definium Therapeutics Reports Positive MDD Trial Results; Two Phase 2 Readouts Anticipated

Definium Therapeutics announced successful Phase 2 trial results for its major depressive disorder (MDD) drug, DTX-201. The positive data positions the company strongly, indicating rapid and sustained improvements in patients. The trial demonstrated DTX-201's efficacy in treating MDD, achieving statistical significance. This success highlights the drug's potential in a critical therapeutic area. Following this achievement, Definium Therapeutics is preparing for two additional Phase 2 readouts. These upcoming data releases, focusing on DTX-201 for anxiety and insomnia, are expected in the near term and represent key catalysts for the company.